Lilly ADA
Biotech

ADA: Lilly offers deeper glimpse into triple-G obesity candidate

Eli Lilly is keenly aware that the one-size-fits-all approach to obesity and diabetes treatment pioneered by early GLP-1s will soon be obsolete.
Fraiser Kansteiner Jun 6, 2026 3:28pm
Firefly

J&J makes $1B bet on emerging DAC space by netting Firefly Bio

Jun 8, 2026 10:05am
FranchiseKeyvisualsOncologyLevel2Digital-nonepng

Could engaging the immune system improve AML outcomes?

Brought to you by Ipsen
Pfizer ADA

ADA: Pfizer pads case for berobenatide in obesity

Jun 6, 2026 9:29am
Roche

Roche bets $700M upfront on Nurix’s late-phase BTK degrader

Jun 8, 2026 4:41am
Boehringer Ingelheim ADA2026 BI

ADA: Tolerability questions linger for Boehringer's obesity drug

Jun 8, 2026 4:30am
More News

Treeline sees path to public markets via reverse merger

Jun 8, 2026 10:37am

Incyte inks $2B deal to add Star biz to late-phase constellation

Jun 8, 2026 9:07am

GSK pledges £44M to UK biotech to explore fibrosis regression

Jun 8, 2026 8:50am

ADA: Roche, Zealand make tolerability case for petrelintide

Jun 7, 2026 3:00am